Management Team

Proven track record in biotech, pharma, product development and finance

Dr. Adi Hoess

Chief Executive Officer (CEO)

Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer and since September 2011 has led the company as CEO. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&A.

read more

Prior to joining Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and CEO of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the M&A process of Jerini AG with Shire. From 2000 – 2002 Dr. Hoess was General Manager and VP of the Molecular Medicine Division at Carl-Zeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, VP of Licensing and BD.

Dr. Hoess received his PhD in chemistry and biochemistry from the University of Munich in 1991, and he also received an M.D. from the Technical University (TU) of Munich in 1997. From 1991 until 1993 Dr. Hoess work as a post doc at the Dana-Farber Cancer Institute at the Harvard Medical School in Boston, USA.

read less

Dr. Wolfgang Fischer

Chief Operating Officer (COO)

Dr. Wolfgang Fischer joined the Company in 2017 from Sandoz Biopharmaceuticals (Novartis Group). He has 20 years of experience in research and drug development with a focus on oncology, immunology and pharmacology.

read more

At Sandoz he managed the development and registration of Sandoz’ biosimilar pipeline assets since 2012 and served as Global Head of Program and Project Management since 2014. Prior to joining Sandoz, he held various positions of increasing responsibility within the Novartis Group since 2003, including Medical Director Oncology for Novartis Pharma Switzerland AG as well as Regional Medical Director Hematology (Emerging Growth Markets), where he was responsible for the Hematology Medical Affairs program and supported the launch of several products in various countries.

Wolfgang Fischer holds a Ph.D. in Cancer Research from the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Thereafter, he completed postdoctoral fellowships at the Swiss Institute of Experimental Cancer Research, Lausanne, Switzerland and at the Scripps Research Institute, Department of Immunology, La Jolla, CA, USA, followed by a state doctorate (Habilitation) in Pharmacology and Toxicology at the Medical School of the University of Würzburg in Germany in 2003.

read less

Denise Mueller

Chief Business Officer (CBO)

Ms. Mueller joined us in 2016 following a 17 year career at Wyeth and Pfizer Inc. She has held leadership roles in U.S. and global marketing including launch of new products and line extensions in-line and globally.

read more

Ms. Mueller has also held the position of Disease Area Lead for multiple therapeutic areas where she was responsible for disease area strategy, indication strategy for multiple assets, early commercial development and market shaping.

In addition to broad and extensive commercial experience, Ms. Mueller led and managed two of Pfizer’s largest alliances and was the business development lead for Pfizer’s rare disease business unit. Prior to joining pharmaceuticals, Ms. Mueller worked in hospital management running Emergency Medicine, Critical Care, in-house Pediatrics and hospitalist programs. Ms. Mueller holds a B.A. in Mathematics from Virginia Polytechnic and State University.

read less

Dr. Cassandra Choe-Juliak

Acting Chief Medical Officer

Dr. Cassandra Choe-Juliak has joined Affimed in 2017 as Vice President of Clinical Development and was appointed Interim Chief Medical Officer in November 2019. She has more than 13 years of industry experience with a focus on drug development in immuno-oncology for hematological and solid tumor malignancies.

read more

In a number of positions at pharmaceutical and biotech companies, Dr. Choe-Juliak gained experience in designing and executing all phases of clinical trials, from phase 1 to registration-directed phase 2/3 studies, as well as regulatory agency interactions. Prior to Affimed she served as the Head of Clinical Development for multiple myeloma and sarcoma at Karyopharm Therapeutics where she was instrumental in generating clinical data that led to the accelerated approval of selinexor. Other previous positions include accompanying the launch of pembrolizumab as Oncology Scientific Director of Merck & Co. and help leading the medical affairs strategy for lanreotide as Medical Director at Ipsen Biopharmaceuticals.

Dr. Choe-Juliak holds a Doctor of Medicine and a Master of Science in Pharmacology and Toxicology from the Medical College of Virginia.

read less

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.